Open Access

Serum fucosylated receptor expression‑enhancing protein 5 as a biomarker for early stage pancreatic cancer

  • Authors:
    • Kazuyuki Sogawa
    • Riko Yonekubo
    • Momori Shimizu
    • Satoshi Muraoka
    • Jun Adachi
    • Shigetsugu Takano
    • Hirotaka Takizawa
    • Masayuki Ohtsuka
    • Takeshi Tomonaga
  • View Affiliations

  • Published online on: September 26, 2025     https://doi.org/10.3892/ol.2025.15302
  • Article Number: 556
  • Copyright: © Sogawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and is a leading cause of cancer mortality. Early diagnosis is difficult due to the anatomical characteristics of the pancreas, which is a long and thin organ located dorsal to the stomach and large intestine. The aim of the present study was to search for protein biomarkers for PDAC in serum extracellular vesicles (EVs) using mass spectrometry, and to validate identified biomarkers using an enzyme‑linked immunosorbent assay (ELISA) of sera from patients. Comprehensive and targeted proteomic analyses for biomarker discovery and verification were performed using EVs from serum of patients with PDAC, patients with chronic pancreatitis (PT) and healthy volunteers (HVs). For validation, the discriminatory power of candidate proteins was evaluated using an ELISA. Of the 3,043 proteins analyzed, 45 were identified as potential biomarkers, with receptor expression‑enhancing protein 5 (REEP5) selected for further analysis. The serum level of fucosylated REEP5 was significantly higher in PDAC cases compared with in PT and HVs (P<0.001). The areas under the curve (AUC) of the receiver operator characteristic were 0.928 for fucosylated REEP5 and 0.805 for carbohydrate antigen 19‑9 (CA19‑9) in PDAC vs. non‑cancer controls. The AUCs were 0.962 for fucosylated REEP5 and 0.810 for CA19‑9 in stages I and II of PDAC. These results indicate that fucosylated REEP5 is a novel serum EV biomarker for detection of early stage PDAC. Further analysis in a larger cohort is warranted to evaluate the clinical utility of fucosylated REEP5 as a biomarker for PDAC.
View Figures
View References

Related Articles

Journal Cover

December-2025
Volume 30 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sogawa K, Yonekubo R, Shimizu M, Muraoka S, Adachi J, Takano S, Takizawa H, Ohtsuka M and Tomonaga T: Serum fucosylated receptor expression‑enhancing protein 5 as a biomarker for early stage pancreatic cancer. Oncol Lett 30: 556, 2025.
APA
Sogawa, K., Yonekubo, R., Shimizu, M., Muraoka, S., Adachi, J., Takano, S. ... Tomonaga, T. (2025). Serum fucosylated receptor expression‑enhancing protein 5 as a biomarker for early stage pancreatic cancer. Oncology Letters, 30, 556. https://doi.org/10.3892/ol.2025.15302
MLA
Sogawa, K., Yonekubo, R., Shimizu, M., Muraoka, S., Adachi, J., Takano, S., Takizawa, H., Ohtsuka, M., Tomonaga, T."Serum fucosylated receptor expression‑enhancing protein 5 as a biomarker for early stage pancreatic cancer". Oncology Letters 30.6 (2025): 556.
Chicago
Sogawa, K., Yonekubo, R., Shimizu, M., Muraoka, S., Adachi, J., Takano, S., Takizawa, H., Ohtsuka, M., Tomonaga, T."Serum fucosylated receptor expression‑enhancing protein 5 as a biomarker for early stage pancreatic cancer". Oncology Letters 30, no. 6 (2025): 556. https://doi.org/10.3892/ol.2025.15302